• AXLhigh Myeloid Cells and mTOR Inhibition in LCH Pathogenesi

  2026-06-20

  This study identifies expansion of circulating AXLhigh/CD207+ myeloid cells as a strong pathognomonic marker in Langerhans cell histiocytosis (LCH), and reveals that mTOR pathway inhibition at early monocyte-to-LC differentiation stages enhances Langerin (CD207) and NOTCH1 expression. These insights refine disease-marker stratification and highlight previously unrecognized effects of mTOR modulation on LCH program initiation.

• Superoxide Dismutase (SOD) Activity Assay Kit: Practical Gui

  2026-06-19

  The Superoxide Dismutase (SOD) Activity Assay Kit (SKU: K2035) enables quantitative measurement of SOD enzyme activity in biological fluids, supporting oxidative stress and antioxidative enzyme research. It is not suitable for diagnostic or clinical applications and should only be used for scientific investigations where rigorous quantitation of SOD activity is required.

• HyperFluor™ 488 Goat Anti-Rabbit IgG: Practical Laboratory G

  2026-06-19

  HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody addresses the technical need for sensitive, specific detection of rabbit primary antibodies in fluorescence-based immunoassays. Its affinity purification and 488 nm fluorophore conjugation suit workflows such as immunofluorescence, immunocytochemistry, and flow cytometry. This reagent is not appropriate for non-rabbit primaries, non-fluorescent detection systems, or sodium azide-incompatible protocols.

• Ceftolozane/Tazobactam: Expanding β-Lactam Options Against R

  2026-06-18

  This review details the innovation and clinical relevance of ceftolozane/tazobactam as a novel β-lactam/β-lactamase inhibitor combination. The study highlights its activity against multidrug-resistant Gram-negative pathogens, especially Pseudomonas aeruginosa and ESBL-producing Enterobacteriaceae, and discusses pharmacokinetic and pharmacodynamic considerations critical to translational research.

• Gallein: G Protein βγ Subunit Inhibitor for Translational Mo

  2026-06-18

  Gallein offers precise, selective inhibition of the G protein βγ subunit, enabling actionable modulation of GPCR signaling in cancer, immunology, and cardiometabolic workflows. Its utility spans complex 3D cancer assays, macrophage polarization studies, and in vivo models of disease, making it a cornerstone for dissecting G protein–mediated mechanisms with translational impact.

• Haloprogin as a Broad-Spectrum Antifungal: Applied Workflows

  2026-06-17

  Haloprogin bridges bench and translational research with robust antifungal and selective antibacterial potency. This article delivers precise workflows, optimization tips, and troubleshooting guided by primary literature, enabling advanced studies in dermatophyte and Candida infection models.

• Prednisone for Immunology Benchwork: Protocols & Troubleshoo

  2026-06-17

  Prednisone, a synthetic corticosteroid, enables precise modeling of immunosuppressive and apoptotic mechanisms in translational research. This article equips researchers with detailed workflows, actionable troubleshooting, and advanced protocol refinements that maximize reproducibility and insight using APExBIO’s high-purity Prednisone.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-06-16

  Schwartz's dissertation critically redefines how in vitro drug responses are measured by distinguishing between proliferative arrest and cell death. This nuanced approach allows for a more accurate understanding of anticancer drug efficacy and supports the design of more predictive preclinical assays.

• Ribociclib Succinate (LEE011): Solubility, pH Dynamics, and

  2026-06-16

  Explore Ribociclib succinate (LEE011 succinate) as a CDK inhibitor for advanced cancer research. This article uniquely analyzes pH-dependent solubility and practical assay decisions, offering deeper insights than existing resources.

• Sulfaphenazole: A Precision CYP2C9 Inhibitor for Vascular Re

  2026-06-15

  Sulfaphenazole delivers unmatched specificity for CYP2C9 inhibition, enabling rigorous control of vascular function, oxidative stress, and antibacterial interventions in advanced preclinical models. Its dual role as a metabolic modulator and wound healing agent sets it apart for translational workflows targeting ischemia-reperfusion injury and drug metabolism studies.

• Scenario-Driven Guidance: FK866 (APO866) for Reliable NAMPT

  2026-06-15

  This article synthesizes laboratory scenarios where FK866 (APO866), SKU A4381, addresses persistent challenges in cell viability and cytotoxicity assays. Emphasizing evidence-based protocols, vendor reliability, and mechanistic selectivity, it equips biomedical researchers with robust, reproducible strategies for hematologic cancer research and NAD metabolism studies.

• Nirmatrelvir (PF-07321332): Strategic Leverage in SARS-CoV-2

  2026-06-14

  This thought-leadership article dissects the mechanistic foundation, experimental value, and translational impact of Nirmatrelvir (PF-07321332) as a premier SARS-CoV-2 3CL protease inhibitor. Bridging the latest biological insights and hands-on workflow guidance, it empowers translational researchers to accelerate antiviral therapeutics research and navigate the evolving COVID-19 landscape with scientific rigor.

• CIP2A Drives PKM2 Tetramerization and Oxidative Metabolism i

  2026-06-13

  This study reveals how the oncoprotein CIP2A promotes oxidative phosphorylation in non-small cell lung cancer (NSCLC) by inducing PKM2 tetramer formation and mitochondrial localization. The findings challenge established views of cancer metabolism and suggest new therapeutic targets for NSCLC.

• PERK–JAK1–STAT3 Signaling Drives Pyroptosis in Disc Degenera

  2026-06-12

  This study reveals that unresolved endoplasmic reticulum stress (ERS) in nucleus pulposus cells accelerates pyroptosis and inflammation through PERK-dependent activation of JAK1–STAT3 signaling. These mechanistic insights highlight the PERK/eIF2α/ATF4–JAK1–STAT3 axis as a promising therapeutic target for mitigating intervertebral disc degeneration.

• CTP Solution in mRNA-LNP Synthesis: Precision for Tumor Supp

  2026-06-12

  CTP Solution (100 mM) empowers high-integrity mRNA synthesis for advanced cancer therapies, as exemplified by p21 mRNA-LNP delivery in bladder cancer. This guide demystifies its optimal use, troubleshooting, and real-world workflow integration to maximize translational outcomes.

462 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page